Anúncio
Anúncio

TEVA

TEVA logo

Teva Pharmaceutical Industries Limited - ADR

32.51
USD
Patrocinado
+0.11
+0.32%
08 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

32.61

+0.10
+0.32%

Relatórios de Lucros TEVA

Rácio de surpresa positiva

TEVA separação 13 de 28 últimas estimativas.

46%

Próximo Relatório

Data do Próximo Relatório
28 de jan. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$4.49B
/
$0.70
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+0.31%
/
-10.26%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+6.27%
/
-1.41%

Teva Pharmaceutical Industries Limited - ADR earnings per share and revenue

On 05 de nov. de 2025, TEVA reported earnings of 0.78 USD per share (EPS) for Q3 25, beating the estimate of 0.66 USD, resulting in a 16.50% surprise. Revenue reached 4.48 bilhão, compared to an expected 4.44 bilhão, with a 0.91% difference. The market reacted with a +20.23% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analistas forecast an EPS of 0.70 USD, with revenue projected to reach 4.49 bilhão USD, implying an diminuir of -10.26% EPS, and aumentar of 0.31% in Revenue from the last quarter.
FAQ
For Q3 2025, Teva Pharmaceutical Industries Limited - ADR reported EPS of $0.78, beating estimates by 16.5%, and revenue of $4.48B, 0.91% above expectations.
The stock price moved up 20.23%, changed from $20.46 before the earnings release to $24.60 the day after.
The next earning report is scheduled for 28 de jan. de 2026.
Based on 6 analistas, Teva Pharmaceutical Industries Limited - ADR is expected to report EPS of $0.70 and revenue of $4.49B for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio